Milestone Pharma Files 8-K on Feb 26 for 'Other Event'
Ticker: MIST · Form: 8-K · Filed: Feb 26, 2024 · CIK: 1408443
Sentiment: neutral
Topics: 8-K filing, corporate-update, regulatory-filing
TL;DR
**Milestone Pharma just dropped an 8-K for an 'Other Event' on Feb 26, keep an eye out for details!**
AI Summary
Milestone Pharmaceuticals Inc. filed an 8-K on February 26, 2024, reporting an 'Other Event' and 'Financial Statements and Exhibits'. The filing indicates a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. The company's business address is 1111 Dr. Frederik-Philips Boulevard, Suite 420, Montréal, Québec, H4M 2X6, and its phone number is (514) 336-0444.
Why It Matters
This 8-K filing signals that Milestone Pharmaceuticals Inc. has an event deemed significant enough to warrant immediate disclosure to investors, potentially impacting its operations or financial standing.
Risk Assessment
Risk Level: medium — The filing indicates an 'Other Event' without specific details, which could range from minor to significant, creating uncertainty.
Key Players & Entities
- Milestone Pharmaceuticals Inc. (company) — Registrant
- February 26, 2024 (date) — Date of earliest event reported and filing date
- 1111 Dr. Frederik-Philips Boulevard, Suite 420, Montréal, Québec, H4M 2X6 (company) — Principal executive offices address
- (514) 336-0444 (company) — Registrant's telephone number
- 001-38899 (company) — Commission File Number
FAQ
What is the exact name of the registrant as specified in its charter?
The exact name of the registrant as specified in its charter is MILESTONE PHARMACEUTICALS INC.
What was the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported was February 26, 2024.
What items of information were reported in this 8-K filing?
The items of information reported were 'Other Events' and 'Financial Statements and Exhibits'.
What is the business address of Milestone Pharmaceuticals Inc.?
The business address is 1111 Dr. Frederik-Philips Boulevard, Suite 420, Montréal, Québec, H4M 2X6.
Under which sections of the Securities Exchange Act of 1934 was this current report filed?
This current report was filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 475 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2024-02-26 07:06:50
Filing Documents
- tm247232d1_8k.htm (8-K) — 26KB
- tm247232d1_ex99-1.htm (EX-99.1) — 15KB
- tm247232d1_ex99-1img001.jpg (GRAPHIC) — 13KB
- 0001104659-24-027262.txt ( ) — 234KB
- mist-20240226.xsd (EX-101.SCH) — 3KB
- mist-20240226_lab.xml (EX-101.LAB) — 33KB
- mist-20240226_pre.xml (EX-101.PRE) — 22KB
- tm247232d1_8k_htm.xml (XML) — 4KB
01
Item 8.01. Other Events. On February 26, 2024, Milestone Pharmaceuticals Inc. (the "Company") issued a press release announcing the feedback it received during a Type A meeting with the U.S. Food and Drug Administration (the "FDA") and plans to resubmit the Company's New Drug Application for self-administered etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia to the FDA. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-Kand is incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits. Exhibit No. Description 99.1 Press release, dated February 26, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MILESTONE PHARMACEUTICALS INC. Date: February 26, 2024 By: /s/ Amit Hasija Amit Hasija Chief Financial Officer Principal Financial Officer